Copied
 
 
Formål
Formål
Selskabets formål er at forske i, udvikle, producere og markedsføre farmaceutiske, medicinske og tekniske produkter og ydelser samt anden dertil knyttet virksomhed efter bestyrelsens nærmere bestemmelse. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 20.03.2014 (3691 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 28.11.1931 (33754 dage).
Ingen historik.
Branche
Branche
Fremstilling af farmaceutiske præparater (212000).
Sidst opdateret den 25.12.2007 og angivet som gældende fra 01.01.2008 (5961 dage).
HistorikStartStop
Fremstilling af farmaceutiske præparater (212000)01.01.2008
Medicinalvarefabrikker (244200)18.10.199931.12.2007
Uoplyst (980000)28.11.193117.10.1999
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 28.11.1931 (33754 dage).
Ingen historik.
Form
Virksomhedsform
60.
Sidst opdateret den 22.11.2013 og angivet som gældende fra 28.11.1931 (33754 dage).
Ingen historik.
Kontakt
HistorikStartStop
web@novo.dk12.11.200218.01.2018
Virksomheden har ikke ændret Kontakt i sin levetid.
Ingen nuværende registrering.
Telefon
Telefonnummer
44448888.
Sidst opdateret den 15.11.2002 og angivet som gældende fra 12.11.2002 (7837 dage).
Ingen historik.
Navne
Binavne
Binavne
NORDISK GENTOFTE A/S.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 28.11.1931 (33754 dage).
Ingen historik.
Tegningsregel
Tegningsregel
Selskabet forpligtes ved underskrift (i) af to direktører i forening, (ii) af en direktør eller et bestyrelsesmedlem i forening med bestyrelsens formand eller næstformand eller (iii) af den samlede bestyrelse.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 20.03.2014 (3691 dage).
Fortolkning (6 tegningsmuligheder)
2 direktører +
1 direktør + formanden
1 direktør + næstformanden
1 bestyrelsesmedlem + formanden
1 bestyrelsesmedlem + næstformanden
bestyrelsen
Ingen historik.
Ansatte
27.04.2024
Kapital
27.04.2024
Fra årsrapport
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:DeloitteStatsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State-Authorised Public Accountant
Virksomhedens regnskabsklasse:Reporting class D
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor’s responsibilities for the audit of the consolidated nancial statements and the parent nancial statements section of this auditor’s report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fullled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sucient and appropriate to provide a basis for our opinion. To the best of our knowledge and belief, we have not provided any prohibited non-audit services as referred to in Article 5(1) of Regulation (EU) No 537/2014. We were appointed auditors of Novo Nordisk A/S for the rst time on 25 March 2021 for the nancial year 2021.
Konklusion (revision):OpinionWe have audited the consolidated nancial statements and the parent nancial statements of Novo Nordisk A/S for the nancial year 1 January 2021 – 31 December 2021, which comprise the income statement, balance sheet, equity statement and notes, including a summary of signicant accounting policies, for the Group as well as the Parent, and the statement of comprehensive income and the cash ow statement of the Group (collectively referred to as the "Financial Statements"). The consolidated nancial statements are prepared in accordance with International Financial Reporting Standards as endorsed by the EU and additional requirements of the Danish Financial Statements Act, and the parent nancial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the consolidated nancial statements give a true and fair view of the Group’s nancial position at 31 December 2021, and of the results of its operations and cash ows for the nancial year 1 January 2021 – 31 December 2021 in accordance with International Financial Reporting Standards as endorsed by the EU and additional requirements under the Danish Financial Statements Act. Further, in our opinion, the parent nancial statements give a true and fair view of the Parent’s nancial position at 31 December 2021, and of the results of its operations for the nancial year 1 January 2021 – 31 December 2021 in accordance with the Danish Financial Statements Act. Our opinion is consistent with our Long-form Auditor’s report issued to the Audit Committee and the Board of Directors.
Udtalelse om ledelsesberetningen (revision):Statement on management reviewManagement is responsible for the management review. Our opinion on the consolidated nancial statements and the parent nancial statements døs not cover the management review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated nancial statements and the parent nancial statements, our responsibility is to read the management review and, in doing so, consider whether the management review is materially inconsistent with the consolidated nancial statements and the parent nancial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the management review is in accordance with the consolidated nancial statements and the parent nancial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management review.
Bibranche
Bibranche
Fremstilling af andre organiske basiskemikalier.
Sidst opdateret den 10.01.2008 og angivet som gældende fra 01.01.2008 (5961 dage).
HistorikStartStop
Fremstilling af andre organiske basiskemikalier01.01.2008
Fremstilling af andre organiske basiskemikalier18.10.199931.12.2007
Børsnoteret
27.04.2024
Børsnoteret
true.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 01.01.2005 (7056 dage).
Ingen historik.
Hjemmeside
27.04.2024
Ingen nuværende registrering.
Ingen historik.